Association of (pro)renin receptor mRNA expression with angiotensin-converting enzyme mRNA expression in human artery

Tomoko Takemitsu1, Atsuhiro Ichihara, Yuki Kaneshiro

  • 1Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Abstract

Insights

The (pro)renin receptor plays a role in arterial angiotensin II generation in kidney failure patients. Its expression is linked to ACE levels, particularly in untreated hypertensive individuals.

Area of Science:

  • Cardiovascular Research
  • Renal Medicine
  • Molecular Biology

Background:

  • The role of the (pro)renin receptor in end-organ damage is primarily suggested by animal studies.
  • Its involvement in human arterial pathology remains largely uncharacterized.

Purpose of the Study:

  • To investigate the messenger RNA (mRNA) expression of the (pro)renin receptor in human arteries.
  • To explore the relationship between (pro)renin receptor expression and components of the renin-angiotensin system in kidney failure patients.

Main Methods:

  • Arterial fragments were obtained from 141 kidney failure patients undergoing arteriovenous access surgery.
  • mRNA expression levels of the (pro)renin receptor and other renin-angiotensin system components were quantified.

Main Results:

  • Arterial (pro)renin receptor mRNA levels were comparable between diabetic and non-diabetic patients, despite higher plasma prorenin in diabetics.
  • Hypertensive patients treated with ACE inhibitors or ARBs showed higher arterial (pro)renin receptor mRNA than untreated patients.
  • A significant association between arterial (pro)renin receptor mRNA and ACE mRNA was observed, which diminished with ACE inhibitor or ARB treatment.

Conclusions:

  • The (pro)renin receptor may contribute to the local production of angiotensin II within arteries of kidney failure patients.
  • Arterial (pro)renin receptor expression is potentially influenced by renin-angiotensin system modulating therapies.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...